Floatz logo

Paltimatrectinib

Brain Tumor, Primary

Pyramid BiosciencesSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Brain Tumor, Primary cohort.

Asset / SponsorPhaseRating
4-demethyl-4-cholestryloxycarbonylpenclomedine
DEKK-TEC, Inc.
Phase 2B
Rvp-001
Reveal Pharmaceuticals Inc.
Phase 2B
Entrectinib
Hoffmann-La Roche
Phase 2CCC
5-ala
Constantinos Hadjipanayis
Phase 2CCC
Capecitabine
Northwell Health
Phase 1/2CCC

View all 28 →

Same molecule, other indications

Paltimatrectinib is also rated in:

desmoplastic small round cell tumorDormant
CC
Indicative ·
43 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →